Kymera Therapeutics (KYMR) Investor Presentation - Slideshow

Kymera Therapeutics Overview - Kymera Therapeutics is building a fully integrated degrader medicines company focused on targeted protein degradation (TPD)[7] - The company's strategy focuses on undrugged targets and clinical indications with high unmet medical needs and franchise potential[7] - Kymera expects 3 INDs and clinical initiations by the end of 2021[8] - As of Q4 2020, Kymera had a cash balance of $459 million, which is expected to fund operational plans into 2025[8,98] IRAK4 Program (KT-474) - KT-474 is a potent, selective, and orally active IRAK4 degrader with potential across various immune-inflammatory diseases[50] - In preclinical studies, KT-474 demonstrated almost complete knockdown across multiple tissues at multiple doses and was well-tolerated up to 600 mg/kg in rodents and 100 mg/kg in non-rodents[43] - A non-interventional study in HS patients showed higher IRAK4 levels in lesional and peri-lesional skin compared to non-lesional skin[45] - Ex vivo incubation of HS blood with KT-474 reduced IRAK4 levels across all PBMC subsets, while an IRAK4 kinase inhibitor increased IRAK4 levels in T and NK cells[47] - Phase 1 SAD portion initiated in Q1 2021, with MAD enrollment expected in 2H 2021 and proof-of-biology data expected in Q4 2021[32,48] IRAKIMiD Program (KT-413) - KT-413 is an IRAKIMiD degrader targeting IRAK4, Ikaros, and Aiolos, with potential as a precision medicine in MYD88-mutant DLBCL[51,53] - Preclinical data shows degradation of IRAK4, Ikaros, and Aiolos correlates to cell killing, with IRAK4 DC50 = 8 nM and Ikaros/Aiolos DC50 = 2 nM[58,60] - KT-413 demonstrated strong tumor regressions in preclinical models with intermittent dosing, with >90% maximum degradation of IRAK4 and Ikaros observed at 3 mg/kg dosing[63,64] - IND submission and Phase 1 clinical trial initiation in r/r B cell lymphomas is expected in 2H 2021, with proof-of-biology data expected in 2022[52,71] STAT3 Program (KT-333) - Kymera is developing STAT3 degraders for liquid and solid tumors, as well as autoimmune/fibrotic diseases[74] - Preclinical data demonstrates highly specific degradation of STAT3, with STAT3 being the only protein to be degraded with statistical significance[78] - STAT3 degrader treatment led to >95% decrease of STAT3 levels with DC50 of 15nM and 86 nM in two STAT3-dependent cell lines[79] - Development candidate nomination expected in Q1 2021, with IND submission and Phase 1 clinical trial initiation expected in Q4 2021[74,95]